Enhanced production of macrophage inflammatory protein 2 (MIP-2) by in vitro and in vivo infections with encephalomyocarditis virus and modulation ofmyocarditis with an antibody against MIP-2
C. Kishimoto et al., Enhanced production of macrophage inflammatory protein 2 (MIP-2) by in vitro and in vivo infections with encephalomyocarditis virus and modulation ofmyocarditis with an antibody against MIP-2, J VIROLOGY, 75(3), 2001, pp. 1294-1300
Interleukin-8 (IL-8) is a chemotactic cytokine for neutrophils and lymphocy
tes, Macrophage inflammatory protein 2 (MIP-2) is a murine counterpart of I
L-8. The present study was performed to determine whether MIP-2 aggravates
murine myocarditis. We examined (i) the MIP-2-producing activity of encepha
lomyocarditis (EMC) virus-infected cultured macrophages, (ii) serial plasma
MIP-2 levels in EMC virus-induced mice by enzyme-linked immunosorbent assa
y, and (iii) the effects of antimouse MIP-2 monoclonal antibody (MAb) in vi
ce upon myocarditis. The production of MIP-2 increased in an infection dose
- and time-dependent manner in virus-infected RAW 264.7 macrophages. Five-w
eek-old C3H/He mice were inoculated with EMC virus, Plasma MIP-2 levels wer
e significantly elevated in mice on days 7 and 11 postinfection. Mice were
injected subcutaneously with anti-MIP-2 MAb at 10 mug/day (group 2) or 100
mug/day (group 3) on days 0 to 5 and were observed until day 21. Uninfected
control mice (group 1) were prepared. The survival rate was higher in the
anti-MIP-2-treated group (group 3), but not in group 2, than in the control
group. Histopathological analysis revealed that cellular infiltration and
myocardial necrosis with macrophage and T-cell accumulation were less promi
nent in the anti-MIP-2 MAb-treated group, but not in group 2, compared to t
he level in the controls, MIP-2 is an important naturally occurring inflamm
atory cytokine in myocarditis, and anti-MIP-2 MAb treatment may prevent the
inflammatory response.